Notice ID: ddb5dfb0987149fbb6740e0ccfc7d64bAward NoticeAwarded
65--Pharm Manuf/Distr Div - FSA
Awarded on October 28, 2024. The description is published on SAM.gov: Full description on SAM.gov.
Awarded tounder SPE2D225D0001 (source: SAM.gov award notice)• $15.3M
Overview
- Posted
- October 28, 2024
- Notice type
- Award Notice
- NAICS
- 325411: Medicinal and Botanical Manufacturing
- Agency
- Department of WarDEFENSE LOGISTICS AGENCY
Notice details
- Office
- DLA TROOP SUPPORT
- PSC
- 65: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
- Last updated
- Dec 5, 2025
- Award date
- Oct 28, 2024
- Award amount (SAM.gov award notice)
- $15.3M
Identifiers
- Solicitation number
- SPE2D224R0004
- Notice ID
- ddb5dfb0987149fbb6740e0ccfc7d64b
- Award number (PIID)
- SPE2D225D0001
Description
No description in the SAM.gov data feed for this notice.
Award Overview
Award Number
SPE2D225D0001
Award Amount (SAM.gov award notice)
$15.3M
Award Date
Oct 28, 2024
Awardee
Awardee UEI
GQLDJJ8AQNN5
Awardee CAGE Code
1HT23
Original Solicitation
Notice ID: ddb5dfb0987149fbb6740e0ccfc7d64b
Posted Date: Oct 28, 2024
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $78.72Signed Aug 14, 2026
- $27.3Signed Aug 12, 2026
- $535.44Signed Aug 12, 2026
- $147.36Signed Aug 12, 2026
- $85.96Signed Aug 10, 2026
Contacts
Contracting Officer
Primary Contact
LISA QUINN215-737-8787
Documents
No documents available.
Lifecycle
Solicitation:
SPE2D224R0004- Awarded
This opportunity has been awarded.
- AwardedCurrentOct 28, 2024
65--Pharm Manuf/Distr Div - FSA
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Amendment 0004 has been issued to extend the solicitation to July 08, 2025. | 46% | Solicitation | 07/08/2025 |
Solicitation is attached. | 46% | Solicitation | 10/06/2025 |
Solicitation is attached. | 46% | Solicitation | 09/26/2025 |
Celecoxib Capsules Solicitation SPE2D2-25-R-0021. | 46% | Solicitation | 09/25/2025 |
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT). Procurement details follow. Ondansetron ODT 4 MG Tablet in 30 count bottles. Ondansetron ODT 8 MG Tablet in 10 and 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Nancy Fernandez at (445) 737-0713, (Nancy.Fernandez@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is September of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date. *The Ondansetron HCL Tablets will be solicited in a separate acquisition. | 46% | Pre-Solicitation | Open |
Additional Details
Solicitation Number
SPE2D224R0004
Archive Date
Nov 12, 2024